Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2011(8): 0810-0810
DOI: 10.1055/s-0030-1260674
DOI: 10.1055/s-0030-1260674
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag
Stuttgart ˙ New York
Synthesis of PSI-352938
P. G. Reddy, B.-K. Chun, H.-R. Zhang, S. Rachakonda, B. S. Ross*, M. J. Sofia
Pharmasset, Inc., Princeton, USA
Further Information
Publication History
Publication Date:
20 July 2011 (online)
Significance
PSI-352938 is an orally active, nucleotide prodrug that inhibits HCV NS5B polymerase. It is currently in clinical trials for the treatment of hepatitis C. Noteworthy features include broad genotype coverage and a good resistance profile. The synthesis depicted delivered multikilogram quantities of API without recourse to chromatography.